Startseite Kongressberichte 2020 Virtual Edition of the 25th Annual Congress of the European Hematology Association Oral Sessions Chronic Lymphoid Neoplasms Multiple Myeloma Multiple Myeloma:

Myeloma biology and translational research

 
Mehmet Samur, Anil Aktas Samur, Mariateresa Fulciniti, et al.
 
The authors of the abstract conclude: 
To date, a great deal of effort has gone into identifying high-risk MM patients, however, little attention has been paid to identify good-risk group with prolonged survival to consider limited therapeutic exposure to mitigate toxicity and improve quality of life. A prospective study to identify, within this group, patients who have potentially curative outcome with sustained MRD negativity as well as a small number of patients who may show persistent small disease burden but behavior akin to MGUS is warranted. It is possible that long term follow-up of the low-risk cohort can provide the key to determine risk status and predict long-term disease control to help identify the path to make this disease chronic or curable in some patients. 
————————————————————————————————————————————————————————
 
 
Arnold Bolomsky, Juho J. Miettinen, Helene Breid, et al.
 
The authors of the abstract conclude: 
This study reveals Bcl-xL as major driver of resistance against MCL1 inhibitors in MM and demonstrates striking activity of the concurrent blockade of BCL-xL and MCL1 in a comprehensive set of preclinical models. Moreover, our findings suggest that different baseline BH3 profiles guide alternative routes to acquired MCL1 inhibitor drug resistance and reveal S63845 as a novel MDR1 substrate. This underlines the importance of identifying clone specific adaptations and the need for careful selection of drug combinations for individualized treatment approaches.
————————————————————————————————————————————————————————
 
 
Madelon de Jong, Zoltan Kellermayer, Natalie Papazian, et al.
 
The authors of the abstract conclude: 
We have identified the presence of activated inflammatory stromal cells in the multiple myeloma stromal niche. These inflammatory stromal cells are reminiscent of pathogenic cancer-associated fibroblasts found in solid tumors, where these cells create a pro-tumorigenic niche that favors tumor survival and proliferation while simultaneously inhibiting anti-cancer immunity. These findings represent the first description of myeloma-specific stromal cell subsets, and provide novel cellular targets for interventions aimed at disrupting the pro-tumorigenic microenvironment in multiple myeloma.
————————————————————————————————————————————————————————
 
 
Anne-Renée van der Vuurst de Vries, Isaac Boss, Aintzane Zabaleta, et al.
 
The authors of the abstract conclude: 
CC-93269 demonstrated T cell-directed antimyeloma activity in MM preclinical models. DEX attenuated cytokine release without affecting CC-93269 antitumor activity. A first-in-human study of CC-93269 in pts with RRMM is ongoing (NCT03486067), showing promising results, and additional clinical trials are planned to start this year. 
————————————————————————————————————————————————————————
 
 
Sonja Seliger, Claudia Haferlach, Wencke Walter, et al.
 
The authors of the abstract conclude: 
(1) MYCr in MM and lymphomas show different characteristics and seem to be generated by different mechanisms.

(2) FISH analysis is a reliable method for the detection of MYCr in lymphoma patients, however complexity and variability of MYCr in MM patients often leads to false negative FISH results.